Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...